Comparison of the efficacy and safety of bimatoprost and timolol for treatment of chronic angle closure glaucoma

Asian Journal of Ophthalmology

Volumn 9, Issue 6, 2007, Pages 239-244

  RojanaPongpun, Prin ^a   Pandav, Surinder S ^b   Reyes, Manolito R ^c   Euswas, Ataya ^d  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c FAR EASTERN UNIVERSITY   (Philippines)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Angle closure; Bimatoprost; Clinical trial; Glaucoma; Timolol

Indexed keywords

EID: 39449096130     PISSN: 15602133     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bourne RR, Sukudom P, Foster PJ, et al. Prevalence of glaucoma in Thailand: a population based survey in Rom Klao District, Bangkok. Br J Ophthalmol. 2003;87:1069-74.
2. He M, Foster PJ, Ge J, et al. Prevalence and clinical characteristics of glaucoma in adult Chinese: a population-based study in Liwan District, Guangzhou. Invest Ophthalmol Vis Sci. 2006;47:2782-8.
3. Foster PJ, Oen FT, Machin D, et al. The prevalence of glaucoma in Chinese residents of Singapore: a cross-sectional population survey of the Tanjong Pagar district. Arch Ophthalmol. 2000;118:1105-11.
4. Vijaya L, George R, Arvind H, et al. Prevalence and causes of blindness in the rural population of the Chennai Glaucoma Study. Br J Ophthalmol. 2006;90:407-10.
5. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-7.
6. Liebmann JM, Ritch A. Laser surgery for angle closure glaucoma. Semin Ophthalmol. 2002;17:84-91.
7. Alsagoff Z, Aung T, Ang LP, Chew PT. Long-term clinical course of primary angle-closure glaucoma in an Asian population. Ophthalmology. 2000;107:2300-4.
8. Rosman M, Aung T, Ang LP, Chew PT, Liebmann JM, Ritch R. Chronic angle-closure with glaucomatous damage: long-term clinical course in a North American population and comparison with an Asian population. Ophthalmology. 2002;109:2227-31.
9. Chew PT, Aung T, Aquino MV, Rojanapongpun P; EXACT Study Group. Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma. Ophthalmology. 2004;111:427-34.
10. Aung T, Chan YH, Chew PT; EXACT Study Group. Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle-closure glaucoma. Ophthalmology. 2005; 112:267-71.
11. Sakai H, Shinjyo S, Nakamura Y, Nakamura Y, Ishikawa S, Sawaguchi S. Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients. J Ocul Pharmacol Ther. 2005; 21:483-9.
12. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(Suppl 4):S347-51.
13. Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology. 2004;111: 1658-62.
14. Brandt JD, VanDenburgh AM, Chen K, Whitcup SM; Bimatoprost Study Group. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology. 2001;108:1023-31; discussion 1032.
15. DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001; 45(Suppl 4):S353-60.
16. Higginbotham EJ, Schuman JS, Goldberg I, et al; Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286-93.
17. Whitcup SM, Cantor LB, VanDenburgh AM, Chen K. A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. Br J Ophthalmol. 2003;87:57-62.
18. Cantor LB, Hoop J, Morgan L, Wudunn D, Catoira Y; Bimatoprost-Travoprost Study Group. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol. 2006;90:1370-3.
19. Agarwal HC, Gupta V, Sihota R. Effect of changing from concomitant timolol pilocarpine to bimatoprost monotherapy on ocular blood flow and IOP in primary chronic angle closure glaucoma. J Ocul Pharmacol Ther. 2003;19:105-12.
20. Chew PT, Rojanapongpun P, Euswas A, et al; Travatan CACG Study Group. Intraocular pressure-lowering effect and safety of travoprost 0.004% and latanoprost 0.005% for the treatment of chronic angle closure glaucoma. Asian J Ophthalmol. 2006;8:13-9.
21. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-79.
22. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 2003;110:609-14.
23. Rait JL, Low CH, Leuenberger EU, et al. Efficacy and safety of bimatoprost for patients with open angle glaucoma or ocular hypertension in the Asia Pacific region. Asian J Ophthalmol. 2005;7:82-90.
24. Wanichwecha-Rungruang B, Iemsomboon W. Efficacy and safety of bimatoprost for the treatment of open-angle glaucoma and ocular hypertension: a three-month, open-label study in community-based practices in Thailand. J Med Assoc Thai. 2005;88:1228-35.
25. Diggory P, Cassels-Brown A, Vail A, Abbey LM, Hillman JS. Avoiding unsuspected respiratory side-effects of topical timolol with cardio-selective or sympathomimetic agents. Lancet. 1995;345:1604-6.
26. Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol. 2000;84:710-3.
27. Gandolfi SA, Chetta A, Cimino L, Mora P, Sangermani C, Tardini MG. Bronchial reactivity in healthy individuals undergoing long-term topical treatment with beta-blockers. Arch Ophthalmol. 2005;123:35-8.